PRIA Logo™
119-hr-4573119th CongressWALLET

Innovate to Save Lives Act

Sponsored By: Representative Neguse, Joe [D-CO-2]

Introduced

Summary

A 10 percent tax credit for small businesses to support drug-threat mitigation research. This bill would create a new nonrefundable credit equal to 10 percent of qualified drug threat mitigation research expenses for eligible small businesses and ties the rules to the existing research credit framework.

Show full summary
  • Small businesses: Offers a new credit equal to 10 percent of qualified drug threat mitigation research expenses for the taxable year. This targets firms that meet the small-business definition in the research credit rules.
  • Researchers and public health projects: Defines "qualified drug threat mitigation research" to include work to mitigate or treat effects of fentanyl, fentanyl-related substances, methamphetamine, and other emerging drugs. Clinical research is allowed only if it follows National Institutes of Health policies and guidelines.
  • Oversight and reporting: Requires a Government Accountability Office report 5 years after enactment on the amount of credits claimed and the types of research supported, with protections for data anonymity and no interference with studies.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

Analyzed Economic Effects

1 provisions identified: 1 benefits, 0 costs, 0 mixed.

Small business credit for drug research

If enacted, eligible small businesses could claim a new nonrefundable tax credit. The credit would equal 10% of qualifying research costs to prevent, treat, or reduce harms from specified drugs. Covered drugs would include fentanyl, fentanyl-related substances, methamphetamine, and drugs named an "emerging drug threat" by federal authorities. Clinical research would be excluded unless it follows NIH clinical research rules. The credit would apply to tax years beginning after enactment and would use the existing R&D credit small-business test.

Sponsors & CoSponsors

Sponsor

Neguse, Joe [D-CO-2]

CO • D

Cosponsors

  • Rep. Ciscomani, Juan [R-AZ-6]

    AZ • R

    Sponsored 7/21/2025

  • Rep. Dean, Madeleine [D-PA-4]

    PA • D

    Sponsored 7/21/2025

  • Rep. Bacon, Don [R-NE-2]

    NE • R

    Sponsored 7/21/2025

  • Rep. Dexter, Maxine [D-OR-3]

    OR • D

    Sponsored 7/21/2025

  • Rep. Lawler, Michael [R-NY-17]

    NY • R

    Sponsored 7/21/2025

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation